In situ coronary stent paving by Pluronic F127–alginate gel blends: Formulation and erosion tests

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 104, Issue 5, 2016, Pages 1013-1022

  Dalmoro, Annalisa ^a   Barba, Anna Angela ^a   Grassi, Mario ^b   Grassi, Gabriele ^b,c   Lamberti, Gaetano ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

coronary stent; drug delivery; erosion phenomena; gel erosion; pluronic alginate blends

Indexed keywords

BIOCOMPATIBILITY; DISEASES; DRUG DELIVERY; DRUG DOSAGE; EROSION; HEART; HYDRAULIC EQUIPMENT; HYDRAULIC MACHINERY; HYDROGELS; PAVEMENTS; PHYSIOLOGY; SPECTROPHOTOMETRY;

CIRCULATORY APPARATUS; CORONARY STENTS; EXPERIMENTAL PROTOCOLS; HUMAN BODY TEMPERATURE; IN-STENT RESTENOSIS; PHYSIOLOGICAL TEMPERATURE; PLURONICS; SPECTRO-PHOTOMETRIC METHOD;

STENTS;

ALGINIC ACID; BUFFER; COPPER ION; DIVALENT CATION; POLOXAMER;

ARTERY WALL; ARTICLE; ATHEROMA; BARE METAL STENT; BODY TEMPERATURE; COBALT CHROMIUM ALLOY STENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG ELUTING CORONARY STENT; GEL; GELATION; GRAVIMETRY; IN SITU GEL PAVING; IN VITRO STUDY; IN-STENT RESTENOSIS; MATERIALS TESTING; PERISTALTIC PUMP; PHYSICAL RESISTANCE; PLURONIC ALGINATE GEL; SELF EXPANDABLE METALLIC STENT; SHEAR STRESS; SILASTIC TUBE; SIMULATION; SIMULATOR; SPECTROPHOTOMETRY; WARMING;

EID: 84976484527     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.33425     Document Type: Article

References (51)

1. Dong Q-Y, Chen M-Y, Xin Y, Qin X-Y, Cheng Z, Shi L-E, Tang Z-X. Alginate-based and protein-based materials for probiotics encapsulation: A review. Int J Food Sci Technol 2013;48:1339–1351.
2. Sun J, Tan H. Alginate-based biomaterials for regenerative medicine applications. Materials 2013;6:1285–1309.
3. Tønnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm 2002;28:621–630.
4. Escobar-Chávez J, López-Cervantes M, Naik A, Kalia Y, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharm Sci 2006;9:339–358.
5. Grassi G, Noro E, Farra R, Guarnieri G, Lapasin R, Grassi M, Matricardi P, Coviello T, DalCortivo A, Alhaique F. Rheological and mechanical properties of Pluronic-alginate gels for drug-eluting stent coating. J Control Release 2006;116:e85–e87.
6. Dalmoro A, Barba AA, Lamberti G, Grassi M, d'Amore M. Pharmaceutical applications of biocompatible polymer blends containing sodium alginate. Adv Polym Technol 2012;31:219–230.
7. Grassi G, Scaggiante B, Dapas B, Farra R, Tonon F, Lamberti G, Barba A, Fiorentino S, Fiotti N, Zanconati F, Abrami M, Grassi M. Therapeutic potential of nucleic acid-based drugs in coronary hyper-proliferative vascular diseases. Curr Med Chem 2013;20:3515–3538.
8. Chandrasekar B, Tanguay J-F. Platelets and restenosis. J Am Coll Cardiol 2000;35:555–562.
9. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 2002;39:183–193.
10. Kathuria YP. Some aspects of drug eluting stents. Int J Cardiol 2007;119:380–383.
11. Garg S, Serruys PW. Coronary stents current status. J Am Coll Cardiol 2010;56:S1–S42.
12. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliver Rev 2006;58:387–401.
13. van der Hoeven BL, Pires NMM, Warda HM, Oemrawsingh PV, van Vlijmen BJM, Quax PHA, Schalij MJ, van der Wall EE, Jukema JW. Drug-eluting stents: Results, promises and problems. Int J Cardiol 2005;99:9–17.
14. Waksman R. Drug-eluting stents: From bench to bed. Cardiovasc Radiat Med 2002;3:226–241.
15. Abrami M, D'Agostino I, Milcovich G, Fiorentino S, Farra R, Asaro F, Lapasin R, Grassi G, Grassi M. Physical characterization of alginate–Pluronic F127 gel for endoluminal NABDs delivery. Soft Matter 2014;10:729–737.
16. Werth D, Grassi G, Konjer N, Dapas B, Farra R, Giansante C, Kandolf R, Guarnieri G, Nordheim A, Heidenreich O. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. Eur J Cell Biol 2010;89:216–224.
17. Dapas B, Farra R, Grassi M, Giansante C, Fiotti N, Uxa L, Rainaldi G, Mercatanti A, Colombatti A, Spessotto P. Role of E2F1–cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs. Mol Med 2009;15:297.
18. Platz J, Grassi M, Kuhn A, Kandolf R, Racchi G, Farra R, Dapas B, Pascotto A, Giansante C, Fiotti N. Effects of various promoter derived sequences on the cleavage kinetic of an hammerhead ribozyme directed against cyclin E1 mRNA. Drug Metab Lett 2007;1:218–225.
19. Agostini F, Dapas B, Farra R, Grassi M, Racchi G, Klingel K, Kandolf R, Heidenreich O, Mercatanti A, Rainaldi G. Potential applications of small interfering RNAs in the cardiovascular field. Drugs Future 2006;31:513–525.
20. Grassi G, Schneider A, Engel S, Racchi G, Kandolf R, Kuhn A. Hammerhead ribozymes targeted against cyclin E and E2F1 cooperate to down-regulate coronary smooth muscle cell proliferation. J Gene Med 2005;7:1223–1234.
21. Grassi G, Dawson P, Guarnieri G, Kandolf R, Grassi M. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases. Curr Pharm Biotechnol 2004;5:369–386.
22. Gabriele Grassi MG, Johannes Platz, Gerhard Bauriedel, Reinhard Kandolf, Anne Kuhn. Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full-length mRNA. Antisense Nucleic Acid Drug Dev 2001;11:271–287.
23. Malmsten M. Soft drug delivery systems. Soft Matter 2006;2:760–769.
24. Malmsten M. Antimicrobial and antiviral hydrogels. Soft Matter 2011;7:8725–8736.
25. Malmsten M, Lindman B. Self-assembly in aqueous block copolymer solutions. Macromolecules 1992;25:5440–5445.
26. Alexandridis P, Alan Hatton T. Poly (ethylene oxide) poly (propylene oxide) poly (ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: Thermodynamics, structure, dynamics, and modeling. Colloids Surf A 1995;96:1–46.
27. Alexandridis P, Holzwarth JF, Hatton TA. Micellization of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) triblock copolymers in aqueous solutions: Thermodynamics of copolymer association. Macromolecules 1994;27:2414–2425.
28. DeRamos CM, Irwin AE, Nauss JL, Stout BE. 13C NMR and molecular modeling studies of alginic acid binding with alkaline earth and lanthanide metal ions. Inorg Chim Acta 1997;256:69–75.
29. Barba AA, d'Amore M, Grassi M, Chirico S, Lamberti G, Titomanlio G. Investigation of pluronic (c) F127-water solutions phase transitions by DSC and dielectric spectroscopy. J Appl Polym Sci 2009;114:688–695.
30. Prud'homme RK, Wu G, Schneider DK. Structure and rheology studies of poly (oxyethylene-oxypropylene-oxyethylene) aqueous solution. Langmuir 1996;12:4651–4659.
31. Grassi G, Farra R, Noro E, Voinovich D, Lapasin R, Dapas B, Alpar O, Zennaro C, Carraro M, Giansante C. Characterization of nucleic acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices. J Drug Deliver Sci Technol 2007;17:325–331.
32. Grassi G, Crevatin A, Farra R, Guarnieri G, Pascotto A, Rehimers B, Lapasin R, Grassi M. Rheological properties of aqueous Pluronic-alginate systems containing liposomes. J Colloid Interface Sci 2006;301:282–290.
33. Veríssimo M, Pais A, Gomes M. Following HPMC gelation with a piezoelectric quartz crystal. Carbohydr Polym 2010;82:363–369.
34. Meznarich NA, Love BJ. The kinetics of gel formation for PEO−PPO−PEO triblock copolymer solutions and the effects of added methylparaben. Macromolecules 2011;44:3548–3555.
35. Kawarada H, Hirai A, Odani H, lida T, Nakajima A. Structure characterization of alginate and conformational behaviors of various alkali-metal alginates in solution. Polym Bull 1990;24:7.
36. Barba AA, Lamberti G, Rabbia L, Grassi M, Larobina D, Grassi G. Modeling of the reticulation kinetics of alginate/pluronic blends for biomedical applications. Mater Sci Eng C 2014;37:327–331.
37. Seidlitz A, Nagel S, Semmling B, Sternberg K, K Kroemer H, Weitschies W. In vitro dissolution testing of drug-eluting stents. Curr Pharm Biotechnol 2013;14:67–75.
38. Fotaki N. Flow-through cell apparatus (USP apparatus 4): Operation and features. Dissolut Technol 2011;18:46–49.
39. Neubert A, Sternberg K, Nagel S, Harder C, Schmitz K-P, Kroemer HK, Weitschies W. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. J Control Release 2008;130:2–8.
40. Bronzino JD. The biomedical engineering handbook, Vol. 2: Boca Raton, FL, USA: CRC Press; 2000.
41. Kolachalama VB, Tzafriri AR, Arifin DY, Edelman ER. Luminal flow patterns dictate arterial drug deposition in stent-based delivery. J Control Release 2009;133:24–30.
42. Comel L, Crevatin, A., Sbaizero, O., Grassi, G., Lapasin, R., Grassi, M. Studio della fluidodinamica coronarica in presenza di rivestimento interno atto al rilascio di agenti antiproliferativi. 2008 18-21 Maggio 2008; Ravenna. Società Italiana di Reologia. pp 113–118.
43. Johnson K, Sharma P, Oshinski J. Coronary artery flow measurement using navigator echo gated phase contrast magnetic resonance velocity mapping at 3.0 T. J Biomech 2008;41:595–602.
44. Keegan J, Gatehouse PD, Mohiaddin RH, Yang GZ, Firmin DN. Comparison of spiral and FLASH phase velocity mapping, with and without breath-holding, for the assessment of left and right coronary artery blood flow velocity. J Magn Reson Imaging 2004;19:40–49.
45. Garcia D, Camici PG, Durand L-G, Rajappan K, Gaillard E, Rimoldi OE, Pibarot P. Impairment of coronary flow reserve in aortic stenosis. J Appl Physiol 2009;106:113–121.
46. Kaimkhani Z, Ali M, Faruqui A. Coronary artery diameter in a cohort of adult Pakistani population. J Pak Med Assoc 2004;54:258–260.
47. Hundley WG, Lange RA, Clarke GD, Meshack BM, Payne J, Landau C, McColl R, Sayad DE, Willett DL, Willard JE. Assessment of coronary arterial flow and flow reserve in humans with magnetic resonance imaging. Circulation 1996;93:1502–1508.
48. Kim H, Vignon-Clementel I, Coogan J, Figueroa C, Jansen K, Taylor C. Patient-specific modeling of blood flow and pressure in human coronary arteries. Ann Biomed Eng 2010;38:3195–3209.
49. Bernhard S, Möhlenkamp S, Tilgner A. Transient integral boundary layer method to calculate the translesional pressure drop and the fractional flow reserve in myocardial bridges. Biomed Eng Online 2006;5:42.
50. Siepmann J, Kranz H, Bodmeier R, Peppas N. HPMC-matrices for controlled drug delivery: A new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharm Res 1999;16:1748–1756.
51. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circulation 2010;75:1287–1296.